 Johnson Johnsons NYSE: JNJ Janssen unit has inked a licensing deal worth 100 million in upfront cash and 25 million in equity for global licensing rights with Xencor Inc NASDAQ: XNCR. The agreement covers Xencors CD20CD3 bispecific antibody plamotamab currently in Phase 1 testing against B cell malignancies. 